In conclusion, SGLT2 inhibitors hold promise as potential therapeutic candidates for NAFLD, although their long-term efficacy and clinical safety require further investigation. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.